Skip to Main Content

Paper Details

A randomized phase 1b cross-over study of the safety of low-dose pioglitazone for treatment of autosomal dominant polycystic kidney disease.
Clin Kidney J
11
2021
Author NameAffiliation
Susan M PerkinsIndiana University
  • 1 - 1

Datasets

Release 1.2